Abstract 3661: Breaking down the barrier restricting infiltration and differentiation of APC in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies

• Published in: Cancer research (Chicago, Ill.) Vol. 77; no. 13_Supplement; p. 3661
• Main Authors: Evans, Elizabeth E., Bussler, Holm, Mallow, Crystal, Reilly, Christine, Torno, Sebold, Scrivens, Maria, Foster, Cathie, Howell, Alan, Comeau, Stephen R., Balch, Leslie, Knapp, Alyssa, Leonard, John E., Fisher, Terrence L., Hu-Lieskovan, Siwen, Ribas, Antoni, Smith, Ernest S., Zauderer, Maurice
• Format: Journal Article
• Language: English
• Published: 01.07.2017

Abstract Purpose: We expand mechanistic findings in preclinical studies to demonstrate that antibody blockade of Semaphorin 4D (SEMA4D, CD100) reduces expansion of MDSC and shifts the balance of myeloid cells within the TME to facilitate tumor rejection. Efficacy is further enhanced when combined wi...